Tuesday, July 1, 2025 7/1/2025

Interplay between tumor and microenvironment in bone metastasis

Award Number: R01CA259599
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2021
PERIOD OF PERFORMANCE END DATE: 03/31/2026

Group Awards By:

View Award Description

Interplay between tumor and microenvironment in bone metastasis - Prostate cancer (CaP) is the most commonly diagnosed cancer and the second leading cause of cancer death in men over the age of fifty. Bone is the primary site of metastasis in patients whose CaP progresses beyond organ confinement. The absence of curative therapies for metastatic CaP emphasizes the imperative to develop innovative technologies for target-specific delivery of therapeutic agents as well as novel treatment strategies that are efficacious with minimal toxicity. Our investigative team seeks to address different aspects of CaP bone metastasis through a highly integrated and focused research effort that will enhance our comprehension of the mechanisms underlying CaP progression and improve therapeutic strategies to eradicate bone metastases and prevent relapse. Our early work using a subtraction hybridization screen identified two unique genes, i.e., melanoma differentiation associated gene-9 (mda-9) and mda-7/IL-24 from terminally differentiating human melanoma cells. Subsequent research established MDA-9 as a key promoter of cancer invasion and metastasis, whereas MDA-7/IL-24 was recognized as a broad-spectrum anti-cancer therapeutic. Using a newly developed syngeneic pre-clinical model of CaP bone metastasis, we will investigate the interplay between CaP bone metastases and the bone niche orchestrated by MDA-9 and evaluate therapeutic activity of ‘first-in-class’ small molecule inhibitor of MDA-9 (i.e., PDZ1i) for targeting both metastatic CaP cells and the bone niche. By exploiting the exquisite ability and high efficiency of T cells to locate and destroy disseminated cancer cells, especially those in normally inaccessible sites, i.e., bone, we will engineer CaP-reactive T cells to produce MDA-7/IL-24, a unique cancer-selective apoptosis-inducing cytokine, for improved capacity to attack potentially antigenically heterogenous bone metastases. Last, based on the ability of PDZ1i to reprogram the immune niche in the tumor microenvironment, we will combine engineered T cells producing next-generation MDA-7/IL-24 (“Superkine MDA-7/IL-24“, “S7M”), having enhanced secretion and stability, with MDA-9-targeted therapy for synergistic elimination of CaP bone lesions. We anticipate that the insights garnered from these studies will enable a more precise molecular understanding of bone metastasis development for target discovery, rational design of improved cellular immunotherapy, and combinatorial treatment modalities optimized to achieve a maximum therapeutic potential. Successful completion of this multidisciplinary, synergistic research program will provide a rapid path to translate these technologies and strategies into the clinic to safely and effectively manage this most common skeletal complication of CaP.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $470,956 )
2025	2025	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	000	5	3/17/2025	NON-COMPETING CONTINUATION	$423,861
2025	2025	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	001	5	5/22/2025	NON-COMPETING CONTINUATION	$47,095
														Subtotal = $470,956

Issue Date FY: 2024 ( Subtotal = $447,407 )
2024	2024	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	001	4	4/17/2024	NON-COMPETING CONTINUATION	$23,546
2024	2024	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	000	4	3/8/2024	NON-COMPETING CONTINUATION	$423,861
														Subtotal = $447,407

Issue Date FY: 2023 ( Subtotal = $461,537 )
2023	2023	VIRGINIA COMMONWEALTH UNIVERSITY	910 WEST FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	000	3	3/14/2023	NON-COMPETING CONTINUATION	$461,537
														Subtotal = $461,537

Issue Date FY: 2022 ( Subtotal = $461,537 )
2022	2022	VIRGINIA COMMONWEALTH UNIVERSITY	912 W FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	001	2	5/11/2022	NON-COMPETING CONTINUATION	$37,680
2022	2022	VIRGINIA COMMONWEALTH UNIVERSITY	912 W FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	000	2	3/11/2022	NON-COMPETING CONTINUATION	$423,857
														Subtotal = $461,537

Issue Date FY: 2021 ( Subtotal = $470,956 )
2021	2021	VIRGINIA COMMONWEALTH UNIVERSITY	912 W FRANKLIN ST	RICHMOND	VA	23284	RICHMOND CITY	USA	Cancer Biology Research	000	1	2/3/2021	NEW	$470,956
														Subtotal = $470,956

Grand Total All Awards = $2,312,393

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Interplay between tumor and microenvironment in bone metastasis

Award Number: R01CA259599

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2021

PERIOD OF PERFORMANCE END DATE: 03/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer